| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Realized gain on investments | NaN | 0 | 41,542 | 641,823 |
| (gain) loss on disposition of assets | NaN | -77,417 | 4,000 | -9,004 |
| Provision for credit losses (recoveries of) | NaN | NaN | -9,127 | -13,248 |
| Net loss | -9,140,038 | -25,745,725 | -5,886,823 | -15,263,388 |
| Depreciation and amortization | 255,445 | 267,566 | 267,383 | 571,859 |
| Impairment charges | NaN | 18,882,000 | NaN | NaN |
| Stock-based compensation expense | 219,114 | 291,975 | 500,585 | 1,455,493 |
| Common stock issued for financial advisory services | NaN | 0 | 0 | 135,000 |
| Change in fair value of acquisition contingencies | 75,280 | 120,919 | -42,345 | 727,289 |
| Non-cash lease expense | -1,349 | -3,212 | -2,982 | -2,003 |
| Loss from equity method investment | -13,361 | 24,862 | -55,959 | -15,204 |
| Recoveries of credit losses | NaN | 26,006 | NaN | NaN |
| Provision for credit losses | 4,164 | NaN | NaN | NaN |
| Income taxes payable | NaN | -491,848 | -245,085 | 23,290 |
| Inventory obsolescence recoveries | -27,884 | 88,039 | -43,681 | -95,302 |
| Accounts receivable | -103,872 | 130,839 | -164,190 | 65,150 |
| Prepaid expenses and other assets | -3,277 | -655,510 | 759,594 | -690,010 |
| Inventory | -174,162 | -9,519 | -38,353 | -83,399 |
| Deferred revenue | -14,200 | -30,757 | -300 | 5,000 |
| Accounts payable, accrued expenses and other liabilities | 639,080 | 80,469 | 19,734 | -3,213,100 |
| Net cash used in operating activities | -7,846,276 | -6,199,298 | -5,904,585 | -17,033,044 |
| Proceeds from maturities of marketable investment securities | NaN | -94,888 | 2,252,362 | 31,509,485 |
| Purchases of property and equipment | 142,017 | 131,969 | 75,105 | 492,973 |
| Purchases of marketable securities | NaN | 0 | 2,362 | 6,588,577 |
| Investment in joint ventures | NaN | 102,566 | NaN | NaN |
| Net cash (used in) provided by investing activities | -142,017 | -329,423 | 2,174,895 | 24,427,935 |
| Proceeds from exercise of options | NaN | 12,500 | NaN | NaN |
| Issuance of common stock related to at-the-market offering, net of offering costs | NaN | 496,884 | 530,183 | 783,746 |
| Issuance of common stock related to at-the-market offering, net of offering costs | 4,334,670 | 6,460,001 | 3,528,269 | NaN |
| Net cash provided by financing activities | 4,334,670 | 6,969,385 | 4,058,452 | 783,746 |
| Net decrease in cash and cash equivalents | -3,653,623 | 440,664 | 328,762 | 8,178,637 |
| Cash and cash equivalents at beginning of period | 11,884,607 | 11,443,943 | 2,936,544 | NaN |
| Cash and cash equivalents at end of period | 8,230,984 | 11,884,607 | 11,443,943 | NaN |
Co-Diagnostics, Inc. (CODX)
Co-Diagnostics, Inc. (CODX)